Biotechnology

Navidea Biopharm

Navidea Biopharmaceutical Extends Rights Agreement to 2027

Navidea Biopharm released FY2020 Q3 earnings on November 12 After-Market EST, with actual revenue of 268,389 USD and EPS of -0.1278

EKSO Bionics

Profusa

Antelope Enterprise

Cemtrex

FLY-E

Borealis Foods

Zhongchao

ON24

374Water

Jyong Biotech

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

阿里拉姆制藥

Argenx

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap